CS209916B2 - Method of making the esters of 4-halogen-9-fluor-3-oxoandrost-4en and 4-halogen-9-fluor-3-oxoandrosta-1,4-dien-17 beta-thiocarboxyl acid - Google Patents
Method of making the esters of 4-halogen-9-fluor-3-oxoandrost-4en and 4-halogen-9-fluor-3-oxoandrosta-1,4-dien-17 beta-thiocarboxyl acid Download PDFInfo
- Publication number
- CS209916B2 CS209916B2 CS792306A CS230679A CS209916B2 CS 209916 B2 CS209916 B2 CS 209916B2 CS 792306 A CS792306 A CS 792306A CS 230679 A CS230679 A CS 230679A CS 209916 B2 CS209916 B2 CS 209916B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- methyl
- diene
- formula
- compound
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/893,390 US4198403A (en) | 1978-04-05 | 1978-04-05 | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS209916B2 true CS209916B2 (en) | 1981-12-31 |
Family
ID=25401489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS792306A CS209916B2 (en) | 1978-04-05 | 1979-04-04 | Method of making the esters of 4-halogen-9-fluor-3-oxoandrost-4en and 4-halogen-9-fluor-3-oxoandrosta-1,4-dien-17 beta-thiocarboxyl acid |
| CS797273A CS209919B2 (en) | 1978-04-05 | 1979-04-04 | Method of making the esters of the 4-halogen-9-fluor-3-oxo-androst-4-en and 4-halogen-9-fluor-3-oxoandrosta -1,4-dien-17beta-thiocarboxyl acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS797273A CS209919B2 (en) | 1978-04-05 | 1979-04-04 | Method of making the esters of the 4-halogen-9-fluor-3-oxo-androst-4-en and 4-halogen-9-fluor-3-oxoandrosta -1,4-dien-17beta-thiocarboxyl acid |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4198403A (xx) |
| EP (1) | EP0004773B1 (xx) |
| JP (1) | JPS54135761A (xx) |
| AT (1) | ATA251879A (xx) |
| AU (1) | AU4575279A (xx) |
| CS (2) | CS209916B2 (xx) |
| DE (1) | DE2960292D1 (xx) |
| DK (1) | DK136479A (xx) |
| ES (1) | ES479272A1 (xx) |
| FI (1) | FI791088A (xx) |
| GR (1) | GR67274B (xx) |
| IL (1) | IL56991A (xx) |
| IT (1) | IT7967709A0 (xx) |
| NO (1) | NO791141L (xx) |
| PL (2) | PL121569B1 (xx) |
| PT (1) | PT69412A (xx) |
| ZA (1) | ZA791638B (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310466A (en) * | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
| SE8004580L (sv) * | 1980-06-19 | 1981-12-20 | Draco Ab | Farmaceutisk beredning |
| US4340538A (en) * | 1980-07-21 | 1982-07-20 | The Upjohn Company | Process for producing 6α-fluoro-Δ1,4 -3-keto steroids |
| SE8306370D0 (sv) * | 1983-11-18 | 1983-11-18 | Draco Ab | Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions |
| US4599331A (en) * | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| EP0754701B1 (en) * | 1994-04-04 | 1998-08-12 | Meiji Milk Products Company Limited | Novel progesterone compound and use thereof |
| US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
| US20020133032A1 (en) * | 2000-02-25 | 2002-09-19 | Jufang Barkalow | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods |
| US20030085387A1 (en) * | 2000-05-31 | 2003-05-08 | Takahiro Fujiyama | Optical materials and optical part each containing aromatic sulfide compound and aromatic sulfide compound |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| SK287576B6 (sk) * | 2000-08-05 | 2011-03-04 | Glaxo Group Limited | S-fluórmetylester kyseliny 6alfa, 9alfa-difluór-17alfa-[(2- furanylkarboxyl)oxy]-11beta-hydroxy-16alfa-metyl-3-oxo-androsta- 1,4-dién-17beta-karbotiovej, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom, jeho použitie a medziprodukty |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| IL158222A0 (en) * | 2001-04-30 | 2004-05-12 | Glaxo Group Ltd | Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| CA2530680A1 (en) * | 2003-04-04 | 2004-10-14 | Alpharma Aps | Process for the preparation of steroidal carbothioic acid derivatives and intermediates |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| AU2010260177A1 (en) | 2009-06-16 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989686A (en) * | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
| US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
| CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
-
1978
- 1978-04-05 US US05/893,390 patent/US4198403A/en not_active Expired - Lifetime
-
1979
- 1979-03-30 PT PT69412A patent/PT69412A/pt unknown
- 1979-03-31 GR GR58747A patent/GR67274B/el unknown
- 1979-04-02 FI FI791088A patent/FI791088A/fi not_active Application Discontinuation
- 1979-04-02 IL IL56991A patent/IL56991A/xx unknown
- 1979-04-03 DK DK136579A patent/DK136479A/da unknown
- 1979-04-03 DE DE7979300549T patent/DE2960292D1/de not_active Expired
- 1979-04-03 AU AU45752/79A patent/AU4575279A/en not_active Abandoned
- 1979-04-03 EP EP79300549A patent/EP0004773B1/en not_active Expired
- 1979-04-04 PL PL1979222926A patent/PL121569B1/pl unknown
- 1979-04-04 NO NO791141A patent/NO791141L/no unknown
- 1979-04-04 IT IT7967709A patent/IT7967709A0/it unknown
- 1979-04-04 CS CS792306A patent/CS209916B2/cs unknown
- 1979-04-04 PL PL1979214675A patent/PL118567B1/pl unknown
- 1979-04-04 ES ES479272A patent/ES479272A1/es not_active Expired
- 1979-04-04 AT AT0251879A patent/ATA251879A/de unknown
- 1979-04-04 CS CS797273A patent/CS209919B2/cs unknown
- 1979-04-05 JP JP4041379A patent/JPS54135761A/ja active Pending
- 1979-04-05 ZA ZA791638A patent/ZA791638B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK136479A (da) | 1979-10-06 |
| ATA251879A (de) | 1982-04-15 |
| EP0004773B1 (en) | 1981-04-29 |
| JPS54135761A (en) | 1979-10-22 |
| ES479272A1 (es) | 1980-01-16 |
| IT7967709A0 (it) | 1979-04-04 |
| ZA791638B (en) | 1980-11-26 |
| US4198403A (en) | 1980-04-15 |
| PL214675A1 (xx) | 1980-07-28 |
| PL222926A1 (xx) | 1981-01-02 |
| DE2960292D1 (en) | 1981-08-06 |
| NO791141L (no) | 1979-10-08 |
| IL56991A (en) | 1982-01-31 |
| GR67274B (xx) | 1981-06-26 |
| AU4575279A (en) | 1979-10-11 |
| IL56991A0 (en) | 1979-07-25 |
| EP0004773A2 (en) | 1979-10-17 |
| PT69412A (en) | 1979-04-01 |
| FI791088A (fi) | 1979-10-06 |
| PL118567B1 (en) | 1981-10-31 |
| EP0004773A3 (en) | 1979-10-31 |
| CS209919B2 (en) | 1981-12-31 |
| PL121569B1 (en) | 1982-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS209916B2 (en) | Method of making the esters of 4-halogen-9-fluor-3-oxoandrost-4en and 4-halogen-9-fluor-3-oxoandrosta-1,4-dien-17 beta-thiocarboxyl acid | |
| CS203956B2 (en) | Method of producing derivatives of 3-oxoandrostene /or androstadiene/ thiocarboxylic acid | |
| US4187301A (en) | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes | |
| US4263289A (en) | Thio etianic acid derivatives | |
| US4242334A (en) | Corticoid 17-(alkyl carbonates) and processes for their preparation | |
| US4076708A (en) | Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby | |
| US4310466A (en) | Thio etianic acid derivatives | |
| US4261984A (en) | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes | |
| US4226862A (en) | Steroids and process for preparing the same | |
| US4336200A (en) | 17α-Acyloxy-5β-corticoids | |
| JPS596880B2 (ja) | Ｄ−ホモステロイドの製造方法 | |
| US4024131A (en) | 16-Methyl-9α-halo steroid esters, ethers and preparation thereof | |
| US4318853A (en) | 9β,11β-Epoxy-5β-corticoids | |
| US4021459A (en) | Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy 20-keto-pregnenes | |
| US4427591A (en) | Reduced A ring-Δ9(11) -corticoids | |
| US4261986A (en) | 4-Halo etianic acids and derivatives thereof | |
| CS208494B2 (en) | Method of making the alcylesters of the 4-halogen-3-oxoandrosta-1,4-dien-17 beta-cyrboxyl acid | |
| EP0095749B1 (en) | 17-spiroandrostenes | |
| US4278669A (en) | 3-Oxo-4-halo-16β-methylandrost-4-ene 17β-carboxylic acids and esters | |
| CS209915B2 (en) | Method of making the 4-halogenpregna-1,4-dien-3,20-dions | |
| IE43979B1 (en) | 21-acetals and mixed acetals of steroidal 21-aldehydes,intermediates and methods of preparation | |
| CS232737B2 (en) | Method of production of new delta (1,3,5)-3-chloropregnane derivatives | |
| US3408369A (en) | 2-substituted-3-keto-delta4, 6-9beta, 10alpha-steroids | |
| NO129570B (xx) | ||
| FI63947C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3,20-dioxo-7alfa-halogen-4-pregnener och 1,4-pregnadiener |